Posted by ABMN Staff on May 13th, 2024
Design Therapeutics, Inc. (NASDAQ:DSGN – Free Report) – Analysts at Leerink Partnrs lifted their Q2 2024 earnings per share (EPS) estimates for Design Therapeutics in a note issued to investors on Wednesday, May 8th....
More of this article »